Your browser doesn't support javascript.
loading
Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel.
Yu, J; Refsum, E; Perrin, V; Helsingen, L M; Wieszczy, P; Løberg, M; Bretthauer, M; Adami, H O; Ye, W; Blom, J; Kalager, M.
Afiliación
  • Yu J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Refsum E; Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Perrin V; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Helsingen LM; Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Wieszczy P; Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway; Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgrad
  • Løberg M; Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Bretthauer M; Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Adami HO; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway. Electronic address: hans-olov.adami@ki.se.
  • Ye W; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China.
  • Blom J; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
  • Kalager M; Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway.
Ann Oncol ; 33(6): 649-656, 2022 06.
Article en En | MEDLINE | ID: mdl-35276334
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Adenocarcinoma / Colitis Ulcerosa / Enfermedad de Crohn / Tumores Neuroendocrinos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Adenocarcinoma / Colitis Ulcerosa / Enfermedad de Crohn / Tumores Neuroendocrinos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Suecia